Cited by 103Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and ResearchDiabetes Treatment and Management

Association between pre-diabetes and microvascular and macrovascular disease in newly diagnosed type 2 diabetes

Open access
Palladino, Raffaele, Tabak, Adam G, Khunti, Kamlesh, Valabhji, Jonathan, Majeed, Azeem, Millett, Christopher, Vamos, Eszter P·2020·BMJ Open Diabetes Research & Care

Abstract

Objective: The associated risk of vascular disease following diagnosis of type 2 diabetes in people previously identified as having pre-diabetes in real-world settings is unknown. We examined the presence of microvascular and macrovascular disease in individuals with newly diagnosed type 2 diabetes by glycemic status within 3 years before diagnosis. Research design and methods: We identified 159 736 individuals with newly diagnosed type 2 diabetes from the UK Clinical Practice Research Datalink database in England between 2004 and 2017. We used logistic regression models to compare presence of microvascular (retinopathy and nephropathy) and macrovascular (acute coronary syndrome, cerebrovascular and peripheral arterial disease) disease at the time of type 2 diabetes diagnosis by prior glycemic status. Results: Half of the study population (49.9%) had at least one vascular disease, over one-third (37.4%) had microvascular disease, and almost a quarter (23.5%) had a diagnosed macrovascular disease at the time of type 2 diabetes diagnosis. Compared with individuals with glycemic values within the normal range, those detected with pre-diabetes before the diagnosis had 76% and 14% increased odds of retinopathy and nephropathy (retinopathy: adjusted OR (AOR) 1.76, 95% CI 1.69 to 1.85; nephropathy: AOR 1.14, 95% CI 1.10 to 1.19), and 7% higher odds of the diagnosis of acute coronary syndrome (OR 1.07, 95% CI 1.03 to 1.12) in fully adjusted models at time of diabetes diagnosis. Conclusions: Microvascular and macrovascular diseases are detected in 37%–24% of people with newly diagnosed type 2 diabetes. Pre-diabetes before diagnosis of type 2 diabetes is associated with increased odds of microvascular disease and acute coronary syndrome. Detection of pre-diabetes might represent an opportunity for reducing the burden of microvascular and macrovascular disease through heightened attention to screening for vascular complications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2019-001061

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Similar impact on diabetes complications was reported with screening, diagnosis, and comprehensive risk factor management in the U.K. Clinical Practice Research Datalink database.

    “Similar impact on diabetes complications was reported with screening, diagnosis, and comprehensive risk factor management in the U.K. Clinical Practice Research Datalink database (97).”

    From 2. Diagnosis and Classification of Diabetes: <i>Standards of Care in Diabetes—2024</i> (2024) · cites this paper as [97]

    The Methods (Study population; page unavailable) confirm that the study used the UK Clinical Practice Research Datalink, and the Results (Secondary analyses; page unavailable) report lower odds of vascular disease among people with a recorded pre-diabetes diagnosis than among those with pre-diabetes but no diagnostic code. The paper suggests that coding might be associated with more intensive risk-factor management, but it did not measure comprehensive management or establish that screening and management caused a reduction in complications. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Risk models have explored the benefit of intervention, generally finding higher benefit of intervention in those at highest risk, and reduce the risk of diabetes complications.

    “Risk models have explored the bene fi t, in general fi nding higher bene fi t of intervention in those at highest risk (96) (see Section 3, ' Prevention or Delay of Diabetes and Associated Comorbidities ' ) and reduce the risk of diabetes complications (97)”
  • Many people in remission from type 2 diabetes remain in the pre-diabetes range of HbA1c, where cardiovascular disease risk begins to rise.

    “However, many people in remission from type 2 diabetes remain in the pre-diabetes range of HbA1c, where cardiovascular disease risk begins to rise [92, 93].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [4]Ashra NB, Spong R, Carter P, et al A systematic review and metaanalysis assessing the effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes mellitus in routine practice. London, the UK: Public Health England, 2015.

Cited by

Sorted by citations

Authors
Palladino, R., Tabak, A. G., Khunti, K., Valabhji, J., Majeed, A., Millett, C., & Vamos, E. P.
Affiliations
  • Imperial College London (GB)
  • Department of Epidemiology and Public Health, University College London, London, UK
  • University of Leicester (GB)
  • Imperial College Healthcare NHS Trust (GB)
Corresponding author
Palladino, Raffaele
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2020-04
Volume
8
Issue
1
Pages
e001061
ISSN
2052-4897 (ISSN-L)
OpenAlex
W3019785267
Cited by
98
References
50
Citations by year
2026: 12 · 2025: 11 · 2024: 25 · 2023: 15 · 2022: 18 · 2021: 10 · 2020: 7
FWCI
9.43
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by-nc)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc)
Funders
  • National Institute for Health and Care Research
  • Department of Health and Social Care
  • Imperial College London
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
prediabetes, type 2 diabetes, newly diagnosed diabetes, microangiopathy, macroangiopathy, diabetic retinopathy, diabetic nephropathy, acute coronary syndrome, cerebrovascular disease, peripheral arterial disease, glycemic status, vascular complications, screening
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Prediabetic State, Vascular Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review